S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
BNGO · Bionano Genomics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Bionano Genomics Inc (BNGO)
NASDAQ NMS - GLOBAL MARKET
Life Sciences Tools & Services
$1.25
+0.00
(+0.00%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.25
$1.25
$1.28
52-WEEK RANGE
$1.25
$1.00
$2.23
What's happening
- BNGO is up 0.00% today, trading at $1.25. — Live quote
- Volume today (1,934) is well below its 3-month average of 703,470. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.64 actual vs. $-0.70 estimated (+8.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BNGO
-18.63%
vs S&P 500
-31.40%
1-YEAR RETURN
BNGO
-37.12%
vs S&P 500
-51.68%
6-MONTH RETURN
BNGO
-1.19%
3-MONTH RETURN
BNGO
+11.16%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.64
Est. $-0.70
BEAT +8.4%
2026-04-26 (Q1 2026)
$-0.76
Est. $-0.90
BEAT +15.3%
2026-01-26 (Q4 2025)
$-0.03
Est. $-1.43
BEAT +97.9%
2025-10-26 (Q3 2025)
$-1.59
Est. $-1.95
BEAT +18.4%
Valuation Measures & Ratios
Enterprise Value4$14.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.49
Price / Book70.41
EV4 / Revenue0.49
EV4 / EBITDA—
Profit Margin-106.58%
Operating Margin-106.67%
Return on Equity (ROE8)-78.78%
Return on Assets (ROA9)-48.54%
Avg Volume (3M)703,470
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $13.3M | $12.7M | $9.1M | $11.4M | $7.6M |
| P/E | -0.43 | -0.47 | -0.15 | -0.16 | -0.08 |
| Price/Sales | 0.46 | 0.47 | 0.34 | 0.42 | 0.26 |
| Price/Book | 0.42 | 0.34 | 0.18 | 0.25 | 0.16 |
| EV/Revenue | 0.33 | 0.34 | 0.23 | 0.29 | 0.14 |
| EV/EBITDA | -0.43 | -0.40 | -0.11 | — | — |
| ROE | -98.35% | -71.44% | -125.92% | -155.22% | -197.13% |
| ROA | -65.32% | -41.30% | -79.31% | -92.66% | -121.14% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,035,020
Change from Prior Settlement+77.86%
% of Float—
Days to Cover (Short Ratio)2.08
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 21.4% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -106.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -37.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BNGO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M | $6.7M | $7.4M | $6.7M | $6.5M | $6.1M | $7.8M | $8.8M |
| Operating income | -$7.2M | -$7.9M | -$8.5M | -$7.8M | -$8.5M | -$43.9M | -$17.0M | -$31.1M |
| Net income | -$7.4M | -$8.3M | -$8.5M | -$6.9M | -$3.1M | -$44.2M | -$16.2M | -$31.4M |
| EPS (diluted) | $-0.64 | $-0.76 | $-1.59 | $-1.99 | $-1.15 | $-30.92 | $-14.41 | $-35.75 |
| EPS (basic) | $-0.64 | $-0.76 | $-1.59 | $-1.99 | $-1.15 | $-30.92 | $-14.41 | $-35.75 |
| Operating margin | -$88 | -$118 | -$116 | -$116 | -$131 | -$723 | -$219 | -$355 |
| Net margin | -$91 | -$124 | -$115 | -$102 | -$48 | -$729 | -$209 | -$358 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $47.6M | $64.8M | $73.6M | $79.1M | $76.0M | $78.4M | $76.7M | $87.4M |
| Total liabilities | $16.0M | $27.3M | $29.2M | $29.3M | $30.6M | $30.2M | $41.3M | $38.5M |
| Stockholders' equity | $31.6M | $37.5M | $44.4M | $49.8M | $45.4M | $48.2M | $35.4M | $48.9M |
| Total current assets | $24.9M | $39.0M | $45.4M | $48.8M | $42.7M | $44.9M | $39.5M | $47.0M |
| Total current liabilities | $10.0M | $21.2M | $22.9M | $23.0M | $24.2M | $26.4M | $37.3M | $33.0M |
| Cash & equivalents | $3.7M | $3.4M | $3.0M | $3.1M | $3.6M | $3.6M | $9.2M | $8.8M |
| Accounts receivable | $4.4M | $4.1M | $5.2M | $4.5M | $3.5M | $3.4M | $4.8M | $5.3M |
| Inventory | $7.0M | $7.7M | $7.8M | $8.4M | $10.3M | $11.4M | $13.3M | $16.3M |
| Other current assets | — | — | $1.8M | — | — | — | $1.3M | — |
| Property, plant & equipment | $13.0M | $14.0M | $14.8M | $16.2M | $17.3M | $18.3M | $19.2M | $20.0M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $1.7M | $3.0M | $4.3M | $5.7M | $7.0M | $8.4M | $9.7M | $11.0M |
| Other non-current assets | $2.1M | $2.7M | $2.7M | $1.8M | $2.1M | $2.4M | $2.8M | $2.8M |
| Accounts payable | $4.6M | $5.1M | $5.6M | $6.0M | $6.2M | $6.6M | $7.0M | $8.7M |
| Accrued liabilities | $3.5M | $4.0M | $5.5M | $4.7M | $3.4M | $3.9M | $5.6M | $5.9M |
| Deferred revenue (current) | $1.1M | $1.1M | $967.0K | $1.2M | $1.2M | $1.0M | $1.1M | $1.2M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $0 | $0 | $0 | $9.0K |
| Retained earnings | -$735.3M | -$727.9M | -$719.6M | -$711.7M | -$703.2M | -$696.3M | -$693.2M | -$673.1M |
| Accumulated other comprehensive income (loss) | $14.0K | $12.0K | $17.0K | $6.0K | -$10.0K | $14.0K | $27.0K | $1.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$5.7M | -$4.2M | -$5.9M | -$3.5M | -$2.8M | -$6.5M | -$13.3M |
| Investing cash flow | $13.7M | $5.5M | $4.0M | -$4.7M | $2.0M | -$14.1M | $3.0M | -$5.4M |
| Financing cash flow | -$9.7M | $657.0K | $1.6M | $10.1M | $1.5M | $10.9M | $3.9M | $6.0M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $2.3M | $2.3M | $2.3M | $2.4M | $2.4M | $2.4M | $2.4M | $5.6M |
| Share-based compensation | $970.0K | $670.0K | $926.0K | $941.0K | $1.1M | $1.6M | $1.9M | $2.2M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $233.0K | -$1.1M | $674.0K | $1.0M | $141.0K | -$1.4M | -$133.0K | -$942.0K |
| Change in inventory | -$77.0K | $106.0K | -$1.6M | -$1.5M | -$724.0K | -$1.1M | -$2.9M | $2.4M |
| Change in accounts payable | -$500.0K | -$528.0K | -$399.0K | -$254.0K | -$318.0K | -$401.0K | -$1.7M | -$31.0K |
| Purchases of investments | $31.5M | $48.7M | $64.4M | $60.9M | $51.9M | $64.8M | $18.7M | $62.7M |
| Sales/maturities of investments | — | — | $0 | $1.4M | $0 | $0 | $0 | $0 |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M |
| Net income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M |
| EPS (diluted) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 |
| EPS (basic) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 |
| Operating margin | -$117 | -$338 | -$596 | -$474 | -$429 |
| Net margin | -$93 | -$364 | -$644 | -$477 | -$403 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M |
| Stockholders' equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M |
| Total current assets | $45.4M | $39.5M | $140.1M | $157.3M | $272.4M |
| Total current liabilities | $22.9M | $37.3M | $100.0M | $35.9M | $21.8M |
| Cash & equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M |
| Accounts receivable | $5.2M | $4.8M | $9.3M | $7.0M | $4.9M |
| Inventory | $7.8M | $13.3M | $27.6M | $29.8M | $12.4M |
| Other current assets | $1.8M | $1.3M | $976.0K | $2.4M | $1.4M |
| Property, plant & equipment | $14.8M | $19.2M | $23.3M | $18.0M | $10.3M |
| Goodwill | — | — | $0 | $77.3M | $56.2M |
| Intangible assets | $4.3M | $9.7M | $34.0M | $41.1M | $26.8M |
| Other non-current assets | $2.7M | $2.8M | $7.4M | $2.4M | $749.0K |
| Accounts payable | $5.6M | $7.0M | $10.4M | $12.5M | $10.8M |
| Accrued liabilities | $5.5M | $5.6M | $8.1M | $10.6M | $8.6M |
| Deferred revenue (current) | $967.0K | $1.1M | $783.0K | $871.0K | — |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | $0 |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $1.0K | $0 | $0 | $3.0K | $29.0K |
| Retained earnings | -$719.6M | -$693.2M | -$581.2M | -$348.7M | -$216.1M |
| Accumulated other comprehensive income (loss) | $17.0K | $27.0K | $23.0K | -$1.1M | -$539.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M |
| Investing cash flow | -$12.7M | $73.8M | $24.2M | $82.8M | -$278.1M |
| Financing cash flow | $24.0M | -$13.7M | $113.8M | $23.0M | $336.1M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | $9.5M | $14.0M | $13.7M | $9.6M | $3.4M |
| Share-based compensation | $4.5M | $9.7M | $15.2M | $22.4M | $9.7M |
| Deferred income taxes | $0 | $0 | $0 | $1.8M | -$5.8M |
| Change in accounts receivable | $448.0K | -$4.1M | $2.3M | $2.3M | $493.0K |
| Change in inventory | -$4.9M | $587.0K | $4.2M | $23.7M | $15.9M |
| Change in accounts payable | -$1.4M | -$3.4M | -$2.0M | $1.9M | $6.8M |
| Purchases of investments | $241.9M | $233.0M | $111.3M | $84.2M | $313.4M |
| Sales/maturities of investments | $1.4M | $33.3M | $0 | $22.8M | $86.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BNGO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-17 to 2026-09-04
Recent transactions
- Insiders have net bought 8,000 shares over the last 182 days, across 2 purchases and 0 sales.
- Most recent: Luderer Albert (Interim Chief Executive) — Open market purchase of 4,000 shares on 2026-09-04.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)8,000 sh(2 txns)
Sales (open market)0 sh(0 txns)
Net Shares+8,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Luderer Albert | Interim Chief Executive | Open market purchase | 2026-09-04 | 4,000 |
| Dixon Jonathan V. | GENERAL COUNSEL | Tax withholding | 2026-06-03 | 24 |
| OLDAKOWSKI MARK | CHIEF OPERATING OFFICER | Tax withholding | 2026-06-03 | 27 |
| Chaubey Alka | CHIEF MEDICAL OFFICER | Tax withholding | 2026-06-03 | 24 |
| Adamchak Mark | Principal Accounting Officer | Tax withholding | 2026-06-03 | 7 |
| Holmlin R. Erik | PRESIDENT AND CEO | Tax withholding | 2026-02-17 | 51 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-04 | Luderer Albert | Interim Chief Executive | Open market purchase | 4,000 | $1.21 |
| 2026-08-21 | Luderer Albert | Interim Chief Executive | Open market purchase | 4,000 | $1.22 |
| 2026-06-03 | Dixon Jonathan V. | GENERAL COUNSEL | Tax withholding | 24 | $1.30 |
| 2026-06-03 | OLDAKOWSKI MARK | CHIEF OPERATING OFFICER | Tax withholding | 27 | $1.30 |
| 2026-06-03 | Chaubey Alka | CHIEF MEDICAL OFFICER | Tax withholding | 24 | $1.30 |
| 2026-06-03 | Adamchak Mark | Principal Accounting Officer | Tax withholding | 7 | $1.30 |
| 2026-02-17 | Chaubey Alka | CHIEF MEDICAL OFFICER | Tax withholding | 18 | $1.10 |
| 2026-02-17 | Adamchak Mark | Principal Accounting Officer | Tax withholding | 3 | $1.10 |
| 2026-02-17 | Dixon Jonathan V. | GENERAL COUNSEL | Tax withholding | 6 | $1.10 |
| 2026-02-17 | OLDAKOWSKI MARK | CHIEF OPERATING OFFICER | Tax withholding | 20 | $1.10 |
| 2026-02-17 | Holmlin R. Erik | PRESIDENT AND CEO | Tax withholding | 51 | $1.10 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:51 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-06-05 | 8-K | 2026-06-02 | View on SEC.gov → |
| 2026-06-03 | 4 | 2026-06-03 | View on SEC.gov → |
Recent news
Headlines about BNGO (Bionano Genomics, Inc.). Links open the publisher — we don’t host full articles.
-
Bionano Genomics Q2 2026 Earnings: Per-Share Loss Narrower Than Expected - Annual Financial Report
www.dars.gov.et · 2026-10-16 -
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
Yahoo Finance · 2026-09-23 -
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
Yahoo Finance · 2026-09-10 -
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
Yahoo Finance · 2026-09-08 -
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-08-24 -
Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-17 -
Bionano Genomics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha · 2026-08-11 -
Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ...
Yahoo Finance · 2026-08-11
No headlines in this category right now — try “All”.